Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification

NCT02812693 is registered in ClinicalTrials.gov with Joanne Jeter as lead sponsor.

NCT NCT02812693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02812693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
Lead sponsor
Joanne Jeter
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 4, 2016
Completion date
November 20, 2017
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiia skin melanoma, stage iiib skin melanoma, stage iiic skin melanoma, stage iv skin melanoma